Research feed
Recently published diabetes studies added to Dediabetes, summarized and organized by intervention and outcome.
Sorted by publication date. Some studies may have been added to Dediabetes later.
This study evaluated a telehealth intervention aimed at reducing sedentary behavior in older adults with Type 2 diabetes, finding a significant decrease in sedentary time.
This study evaluated the effectiveness of telemonitoring for diabetes management in pediatric patients with type 1 diabetes. The telecounseling group showed significantly better outcomes compared to the standard care group.
This study evaluated the effects of canagliflozin on cardiovascular and kidney outcomes in individuals with type 2 diabetes, finding a reduction in major adverse cardiovascular events.
This study evaluated the impact of Clazakizumab on high-sensitivity C-reactive protein (hs-CRP) levels in patients with cardiovascular disease and diabetes, finding significant decreases in hs-CRP levels with treatment.
This study compared the effects of empagliflozin and pioglitazone on echocardiographic indices in patients with type 2 diabetes and nonalcoholic fatty liver disease, finding significant improvements in certain measures.
This study evaluated the effects of empagliflozin on diastolic function in patients with type 2 diabetes and elevated end-diastolic pressure, finding significant improvements in various cardiovascular and metabolic parameters.
The FIGARO-DKD trial subgroup analysis evaluated finerenone in patients with type 2 diabetes and chronic kidney disease, finding significant reductions in kidney failure risk.
This study analyzed the effects of Multifactorial Therapy (MT) versus Usual Care (UC) in participants with type 2 diabetes, finding significant reductions in major adverse cardiovascular events and all-cause mortality.
The study evaluated the effects of semaglutide on vascular regenerative cell content in individuals with type 2 diabetes, finding significant increases compared to usual care.
The FLOW trial investigated the effects of semaglutide on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease, revealing significant reductions in cardiovascular death, myocardial infarction, and stroke.
